vs
Side-by-side financial comparison of Royalty Pharma plc (RPRX) and UL Solutions Inc. (ULS). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $340.0M, roughly 1.8× UL Solutions Inc.). On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs -12.4%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -31.8%).
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
The UL enterprise is a global private safety company headquartered in Northbrook, Illinois, composed of three organizations, UL Research Institutes, UL Standards & Engagement and UL Solutions.
RPRX vs ULS — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $622.0M | $340.0M |
| Net Profit | $214.2M | — |
| Gross Margin | — | — |
| Operating Margin | 62.4% | 24.4% |
| Net Margin | 34.4% | — |
| Revenue YoY | 4.8% | -12.4% |
| Net Profit YoY | 2.9% | — |
| EPS (diluted) | $0.49 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $340.0M | ||
| Q4 25 | $622.0M | $789.0M | ||
| Q3 25 | $609.3M | $783.0M | ||
| Q2 25 | $578.7M | $776.0M | ||
| Q1 25 | $568.2M | $705.0M | ||
| Q4 24 | $593.6M | $739.0M | ||
| Q3 24 | $564.7M | $731.0M | ||
| Q2 24 | $537.3M | $730.0M |
| Q1 26 | — | — | ||
| Q4 25 | $214.2M | $67.0M | ||
| Q3 25 | $288.2M | $100.0M | ||
| Q2 25 | $30.2M | $91.0M | ||
| Q1 25 | $238.3M | $67.0M | ||
| Q4 24 | $208.2M | $81.0M | ||
| Q3 24 | $544.0M | $88.0M | ||
| Q2 24 | $102.0M | $101.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 49.7% | ||
| Q3 25 | — | 50.3% | ||
| Q2 25 | — | 49.4% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | 47.4% | ||
| Q3 24 | — | 49.0% | ||
| Q2 24 | — | 50.1% |
| Q1 26 | — | 24.4% | ||
| Q4 25 | 62.4% | 15.0% | ||
| Q3 25 | 70.1% | 19.9% | ||
| Q2 25 | 36.3% | 17.9% | ||
| Q1 25 | 94.0% | 15.5% | ||
| Q4 24 | 60.9% | 15.6% | ||
| Q3 24 | — | 17.8% | ||
| Q2 24 | 50.2% | 17.3% |
| Q1 26 | — | — | ||
| Q4 25 | 34.4% | 8.5% | ||
| Q3 25 | 47.3% | 12.8% | ||
| Q2 25 | 5.2% | 11.7% | ||
| Q1 25 | 41.9% | 9.5% | ||
| Q4 24 | 35.1% | 11.0% | ||
| Q3 24 | 96.3% | 12.0% | ||
| Q2 24 | 19.0% | 13.8% |
| Q1 26 | — | — | ||
| Q4 25 | $0.49 | $0.33 | ||
| Q3 25 | $0.67 | $0.49 | ||
| Q2 25 | $0.07 | $0.45 | ||
| Q1 25 | $0.55 | $0.33 | ||
| Q4 24 | $0.46 | $0.40 | ||
| Q3 24 | $1.21 | $0.44 | ||
| Q2 24 | $0.23 | $0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $618.7M | — |
| Total DebtLower is stronger | $9.0B | — |
| Stockholders' EquityBook value | $9.7B | — |
| Total Assets | $19.6B | — |
| Debt / EquityLower = less leverage | 0.92× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $618.7M | $295.0M | ||
| Q3 25 | $938.9M | $255.0M | ||
| Q2 25 | $631.9M | $272.0M | ||
| Q1 25 | $1.1B | $267.0M | ||
| Q4 24 | $929.0M | $298.0M | ||
| Q3 24 | $950.1M | $327.0M | ||
| Q2 24 | $1.8B | $295.0M |
| Q1 26 | — | — | ||
| Q4 25 | $9.0B | $491.0M | ||
| Q3 25 | $8.9B | $544.0M | ||
| Q2 25 | $8.0B | $608.0M | ||
| Q1 25 | $7.6B | $653.0M | ||
| Q4 24 | $7.6B | $742.0M | ||
| Q3 24 | $7.6B | $797.0M | ||
| Q2 24 | $7.6B | $810.0M |
| Q1 26 | — | — | ||
| Q4 25 | $9.7B | $1.3B | ||
| Q3 25 | $9.6B | $1.2B | ||
| Q2 25 | $9.5B | $1.1B | ||
| Q1 25 | $9.8B | $970.0M | ||
| Q4 24 | $10.3B | $904.0M | ||
| Q3 24 | $10.3B | $872.0M | ||
| Q2 24 | $9.8B | $769.0M |
| Q1 26 | — | — | ||
| Q4 25 | $19.6B | $2.9B | ||
| Q3 25 | $19.3B | $2.9B | ||
| Q2 25 | $18.3B | $2.9B | ||
| Q1 25 | $17.6B | $2.9B | ||
| Q4 24 | $18.2B | $2.8B | ||
| Q3 24 | $18.0B | $2.9B | ||
| Q2 24 | $17.7B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.92× | 0.39× | ||
| Q3 25 | 0.93× | 0.46× | ||
| Q2 25 | 0.84× | 0.56× | ||
| Q1 25 | 0.78× | 0.67× | ||
| Q4 24 | 0.74× | 0.82× | ||
| Q3 24 | 0.74× | 0.91× | ||
| Q2 24 | 0.78× | 1.05× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $827.1M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 3.86× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $827.1M | $144.0M | ||
| Q3 25 | $702.6M | $155.0M | ||
| Q2 25 | $364.0M | $147.0M | ||
| Q1 25 | $596.1M | $154.0M | ||
| Q4 24 | $742.5M | $130.0M | ||
| Q3 24 | $703.6M | $150.0M | ||
| Q2 24 | $658.2M | $103.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $86.0M | ||
| Q3 25 | — | $109.0M | ||
| Q2 25 | — | $105.0M | ||
| Q1 25 | — | $103.0M | ||
| Q4 24 | — | $72.0M | ||
| Q3 24 | — | $84.0M | ||
| Q2 24 | — | $47.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 10.9% | ||
| Q3 25 | — | 13.9% | ||
| Q2 25 | — | 13.5% | ||
| Q1 25 | — | 14.6% | ||
| Q4 24 | — | 9.7% | ||
| Q3 24 | — | 11.5% | ||
| Q2 24 | — | 6.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 7.4% | ||
| Q3 25 | — | 5.9% | ||
| Q2 25 | — | 5.4% | ||
| Q1 25 | — | 7.2% | ||
| Q4 24 | — | 7.8% | ||
| Q3 24 | — | 9.0% | ||
| Q2 24 | — | 7.7% |
| Q1 26 | — | — | ||
| Q4 25 | 3.86× | 2.15× | ||
| Q3 25 | 2.44× | 1.55× | ||
| Q2 25 | 12.06× | 1.62× | ||
| Q1 25 | 2.50× | 2.30× | ||
| Q4 24 | 3.57× | 1.60× | ||
| Q3 24 | 1.29× | 1.70× | ||
| Q2 24 | 6.45× | 1.02× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
ULS
Segment breakdown not available.
